New hope for tough lung cancer: Dual-Action drug combo in final testing
Disease control
Ongoing
This phase 3 trial tests a new drug called PM8002, which targets the immune system and tumor blood vessels, combined with the chemotherapy paclitaxel. It is for people with small cell lung cancer whose disease has worsened after initial treatment. The study involves 404 participa…
Phase: PHASE3 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC